Evolus, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Evolus, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-6.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 54% of Healthcare companies in United States.
Cash Locked Ratio
$15For every $100 of sales, $15 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $17 tied up three years earlier.
Less money tied up than 69% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$15Sales grew 100% in 3 years; of every extra $100 of sales, $15 became extra profit.
Lower than 55% of Healthcare companies in United States.
Asset Productivity Ratio
+100% / +27%In 3 years sales changed by +100% while total assets changed by +27%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-16.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 51% of Healthcare companies in United States.
Cash Cushion Ratio
−21%Debt, after subtracting cash, equals 21% of its market value (net debt).
Lower than 84% of Healthcare companies in United States.
Tangible Assets Ratio
69%Of every $100 the company owns, $69 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 62% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Evolus, Inc. made a loss over the last year. Evolus, Inc. owes $1.12 for every $1 it owns. Evolus, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEvolus, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-15.84Evolus, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$489 MThe total market value of all of Evolus, Inc.'s shares at today's price (share price × number of shares), larger than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeEvolus, Inc.'s net worth is negative ($31 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.12×Evolus, Inc. owes $1.12 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Dividend yield
NoneEvolus, Inc. does not currently pay a dividend.
Revenue growth
+12%Revenue rose 12% in the year to Dec 2025, and grew 26% a year on average over 3 years.
Profit growth
LossEvolus, Inc. made a loss in each of the last two years.
Profit margin
-17.4%Evolus, Inc. lost $17 for every $100 of revenue.
Interest cover
Not coveredEvolus, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtEvolus, Inc. had $101 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Evolus, Inc. owe compared with what it owns?
Evolus, Inc. owes $1.12 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Does Evolus, Inc. pay a dividend?
No. Evolus, Inc. does not currently pay a dividend.
Is Evolus, Inc.'s revenue growing?
Revenue rose 12% in the year to Dec 2025, and grew 26% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.